+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Pulmonary Arterial Hypertension: 68-Market Analysis and Sales Forecast

  • PDF Icon

    Report

  • 15 Pages
  • June 2025
  • Region: Global
  • GlobalData
  • ID: 6109255
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Pulmonary Arterial Hypertension market.

Across the 68 markets, sales in the PAH market were $10.1 billion in 2024, growing to $17.9 billion in 2034.
The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 24.5% and 48.0% in 68-market sales in 2024 and 2034, respectively.

Scope

  • This publication is an expanded version of the Excel model containing the patient-based forecast sales for PAH, covered in the analyst’s report “Pulmonary Arterial Hypertension: Seven-Market Drug Forecast and Market Analysis to 2034”, published in June 2025.
  • In addition to patient based forecast sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report contains sales forecast extrapolations for an additional 60 geographical markets (60M), totaling 68 markets (68M).

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the 7MM PAH therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM PAH therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Executive Summary
1.1 Overview
1.2 68M summary statistics
1.3 Key 7MM events driving the 68M forecast extrapolation
2 Appendix
2.1 Abbreviations
2.2 Methodology
2.2.1 Patient-based forecast methodology
2.2.2 68M forecast extrapolation methodology
2.3 Primary research - key opinion leaders and payers interviewed for this report
2.3.1 Key opinion leaders
2.4 Primary research - prescriber survey
2.5 About the authors
2.5.1 Therapy Area Director
2.5.2 Vice President of Disease Intelligence and Epidemiology
2.5.3 Global Head of Pharma Research, Analysis, and Competitive Intelligence
  • About the Analyst
  • Contact the Publisher
List of Tables
Table 1: PAH market size across the 68M - 7MM versus 61M
Table 2: PAH market size across the 68M - by geographical region
Table 3: PAH, key events occurring in the 7MM driving forecast trajectory in the 68M
Table 4: High-prescribing physicians (non-KOLs) surveyed, by country
List of Figures
Figure 1: PAH market size across the 68M - 7MM versus 61M
Figure 2: PAH market size across the 68M - by geographical region

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie Inc
  • Acceleron Pharma Inc
  • Actelion
  • Amgen Inc
  • Bayer AG
  • Bristol Myers Squibb
  • Eli Lilly and Co
  • Entera Bio Ltd
  • Gilead Sciences Inc
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck & Co Inc
  • Novartis International AG
  • Pfizer Inc
  • Roche Holding AG
  • Sanofi
  • Teva Pharmaceutical Industries Ltd
  • UCB S.A.